KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Accumulated Expenses (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Accumulated Expenses for 15 consecutive years, with $107.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 41.19% to $107.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $107.8 million, a 41.19% increase, with the full-year FY2025 number at $107.8 million, up 41.19% from a year prior.
  • Accumulated Expenses was $107.8 million for Q4 2025 at Supernus Pharmaceuticals, down from $108.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $154.3 million in Q4 2023 to a low of $76.4 million in Q4 2024.
  • A 5-year average of $119.4 million and a median of $113.1 million in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 49.09% in 2021, then tumbled 50.51% in 2024.
  • Supernus Pharmaceuticals' Accumulated Expenses stood at $117.7 million in 2021, then increased by 28.88% to $151.7 million in 2022, then increased by 1.72% to $154.3 million in 2023, then crashed by 50.51% to $76.4 million in 2024, then skyrocketed by 41.19% to $107.8 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Accumulated Expenses are $107.8 million (Q4 2025), $108.6 million (Q3 2025), and $76.4 million (Q4 2024).